Form Bio leverages advanced computational technologies to enhance the development of AAV (Adeno-Associated Virus) gene therapies, significantly streamlining the drug development process. Their FORMsight AI platform employs in silico tools that facilitate the design and optimization of gene therapy vectors by assessing genomic identity, immunogenicity, and manufacturability. This technology allows researchers to explore multiple vector designs rapidly, compare the safety and efficacy of various constructs, and predict potential immunotoxicity risks associated with specific genomic patterns. By integrating machine learning and AI-driven insights, Form Bio aims to reduce the time and costs associated with therapeutic development while improving the overall success rates of gene therapies.

Additionally, Form Bio's technology suite includes capabilities for detailed drug substance characterization and bioreactor sample analysis, which are crucial for ensuring the quality and efficacy of manufactured products. Their platform supports end-to-end workflows for long-read sequencing, enabling precise insights into therapeutic candidates and facilitating the identification of optimal constructs for clinical applications. By collaborating with industry leaders and conducting biological validation studies, Form Bio continuously refines its AI models, ensuring that they provide reliable predictions and optimizations that enhance the manufacturability and safety of gene therapy products.

United States

Form empowers scientists to harness the data, computing power and collaboration that drive how today's breakthroughs are made.

Form Bio

Company Details